Biomarkers as Key Contributors in Treating Malignant Melanoma Metastases

Table 3

Emerging immunotherapeutic to treatment of metastatic melanoma.

Target	Drug	Class	Phase(s) trial	Protocol_IDs*
CD40	CP-870,893	Fully human mAb	I	NCT01008527
			I	NCT01103635
CD137	BMS-663513	mAb	I	NCT00803374
Cytokines	Interleukin-21	Recombinant human molecule	II	NCT01152788
CTLA-4	Tremelimumab	Fully human IgG2 mAb	III	[62]
			II	NCT01034787
Immunocytokines	EMD 273063	Humanized anti-GD2 mAb linked to IL-2	II	NCT00590824
α v integrin	CNTO95	mAb	I, II	NCT00246012
α vβ 3 integrin	MEDI-522	Humanized mAb	I	NCT00111696
PD1	MDX-1106	Fully human mAb	I	NCT00730639
			I	NCT01024231
			I	NCT01176461
TGF-β	GC1008	Fully human mAb	I	NCT00899444
TGF-β2	AP12009	Antisense oligonucleotide	I	NCT00844064
TLR regulation of Treg  cells	CpG 7909 (ProMune)	Synthetic oligonucleotide	II	NCT01266603
			No phase specified	NCT00471471

*Randomized clinical trials selected from http://www.clinicaltrials.gov/.